Afluria®
Influenza vaccine trivalent (split virion, inactivated)
Product Details
WHO Product ID
FVP-P-367
Status
Prequalified
Date of prequalification
Vaccine type
Influenza vaccine trivalent (split virion, inactivated)
Abbreviated Name
IIV3
Commercial Name
Afluria®
PQ Holder
Seqirus Australia Pty Ltd
63 Poplar Road
Parkville Victoria,
3052
Australia
Responsible NRA
US Food and Drug Administration- Office of Vaccine Research and Review (US FDA)
Product description
Pharmaceutical Form
Liquid: Ready to use
Presentation
Vial
Number of doses
10
Route of administration
Intramuscular
Vaccine Vial Monitor
Type 2
Multidose Vial Policy
WHO recommends that opened vials of this vaccine may be used in subsequent immunization sessions (up to 28 days) if the conditions outlined in the WHO Policy Statement are met.
Shelf life (months)
15 months
Storage temperature
2 - 8°C
Diluent
N/A
Preservative
Thiomersal
Preservative concentration
0.01%w/v
Remarks
The shelf-life of Afluria TIV MDV is 15 months at 2°C to 8°C.Pallet shipper contains 119 shipping boxes of 952 vials (95200 doses of 0.5 mL or 190400 doses of 0.25 mL)
Product Packaging
Secondary Container
Shipping Container
Component Packed
Active (Vaccine)
Total doses
1
Description
Carton of 1 mulitidose vial (ten 0.5 doses (adult) or twenty 0.25 doses (paedriati
Cold Chain Volume (cm³/dose)
0.0
Component Packed
Active (Vaccine)
Total doses
1
Description
Twenty 0.25 doses (paedriatic)[Dimensions: 3.8 x 6.0 x 3.1 cm]
Dimensions
3.8 x 6.0 x 3.1 cm
Cold Chain Volume (cm³/dose)
3.53